Shots:

• uniQure to receive $2B+ including $450M as up front in cash- $1.6B as regulatory & commercial milestones along with royalties in sales of  AMT-061 (etranacogene dezaparvovec) while CSL Behring to get an exclusive global right to commercialize AMT-061
• uniQure will be responsible for the completion of the P-III HOPE-B study and scale-up manufacture for early commercial supply under an agreed plan with CSL Behring. uniQure will lead clinical development and regulatory activities- reimbursed by CSL Behring
• The collaboration will foster CSL Behring’s gene therapy portfolio while allowing uniQure to expand and accelerate pipeline and platform. The AMT-061 consists of an AAV5 viral vector carrying a gene cassette with FIX-Padua- currently being evaluated in P-III study and could be one of the first gene therapies to provide long-term benefits to patients with hemophilia B

Click here- Click here to read full press release/ article | Ref: CSL Behring- Businesswire | Image: Norwood